# Treating Cannabis Addiction and Withdrawal: Latest Clinical Data > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/treating-cannabis-addiction-and-withdrawal-latest-clinical-data/ > **Published:** 2026-07-07T17:19:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:04:40-04:00 > **Clinical Summary:** Evidence-based cannabis withdrawal treatment strategies for clinicians. Managing addiction, withdrawal symptoms, and patient outcomes. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Mental HealthResearchAnxietySleepSafetyAgingPediatrics Why This Matters Clinicians managing patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) now have updated evidence-based treatment protocols and withdrawal management strategies to improve outcomes and reduce relapse rates. Understanding current pharmacological and behavioral interventions is essential as [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) prevalence continues to rise across age groups, requiring geriatric and adolescent specialists to address addiction appropriately within their respective populations. Equipping clinicians with the latest clinical data on [cannabis addiction treatment](https://cedclinic.com/cannabis-reinforcement-and-dependence-cb1-receptors/) directly improves patient safety, reduces unnecessary emergency department visits, and supports medication-assisted therapy options when indicated. Clinical Summary Recent clinical evidence demonstrates that [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and withdrawal syndrome are recognized psychiatric conditions with measurable symptomatology that can guide clinical management. Current data supports a combination approach using cognitive-behavioral therapy as first-line treatment, with pharmacologic options including gabapentin, buspirone, and selective serotonin reuptake inhibitors showing promise for managing withdrawal symptoms such as irritability, sleep disturbance, and anxiety. Cannabis withdrawal, though generally less severe than alcohol or opioid withdrawal, can significantly impair functioning and increase relapse risk, particularly in heavy users and those with comorbid psychiatric conditions. Age-specific considerations are important, as adolescents show different neurobiological vulnerability to [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/) compared to adults, while older adults may experience more complex medication interactions and psychiatric comorbidities. Treatment outcomes improve substantially when withdrawal management is combined with psychosocial support and management of underlying depression or anxiety that frequently co-occurs with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder. Clinicians should assess all patients for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) using standardized screening tools and offer evidence-based withdrawal management, as timely intervention during the acute withdrawal period significantly increases long-term abstinence rates. Dr. Caplan’s Take “What we’re seeing in the peer-reviewed literature on cannabis withdrawal is that it’s real and measurable in a subset of heavy users, though typically milder than alcohol or opioid withdrawal. The clinical challenge now is matching patients to the right interventions, whether that’s behavioral therapy, symptom management, or in some cases judicious use of medications like CBT or low-dose sleep aids, rather than assuming one approach fits everyone.” Clinical Perspective 💊 As [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands and potency increases, clinicians may encounter more patients seeking treatment for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder and withdrawal symptoms, particularly in geriatric and adolescent populations where neurobiological vulnerabilities differ. Current evidence supports cognitive-behavioral therapy and motivational interviewing as first-line psychosocial interventions, though pharmacological options remain limited and inconsistently effective across patient subgroups. The complexity lies in distinguishing cannabis withdrawal from underlying psychiatric conditions, comorbid substance use, and age-related factors that influence treatment response and tolerability of adjunctive medications. Clinicians should maintain a developmental and developmental lens when assessing dependence severity, as adolescents may present with different withdrawal profiles and treatment needs than older adults with comorbid medical conditions. In practice, a structured assessment of withdrawal severity combined with matched psychosocial support tailored to the patient’s age and psychiatric history offers the most evidence-based approach while 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Treating+Cannabis+Addiction+and+Withdrawal%3A+Latest+Clinical+Data+%40drcaplan&url=https%3A%2F%2Fwww.psychiatrictimes.com%2Fview%2Ftreating-cannabis-addiction-and-withdrawal-latest-clinical-data)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.psychiatrictimes.com%2Fview%2Ftreating-cannabis-addiction-and-withdrawal-latest-clinical-data)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Treating+Cannabis+Addiction+and+Withdrawal%3A+Latest+Clinical+Data+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.psychiatrictimes.com%2Fview%2Ftreating-cannabis-addiction-and-withdrawal-latest-clinical-data)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Ask the Expert: How Is Cannabis Use Disorder Diagnosed and Treated?](https://cedclinic.com/cannabis-use-disorder-diagnosis-criteria-treatment/) - [Effectiveness of Cognitive Behavioral Therapy for Harmful Cannabis Use](https://cedclinic.com/cognitive-behavioral-therapy-cannabis-use-disorder-effectiveness/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.psychiatrictimes.com/view/treating-cannabis-addiction-and-withdrawal-latest-clinical-data](https://www.psychiatrictimes.com/view/treating-cannabis-addiction-and-withdrawal-latest-clinical-data) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).